%0 Journal Article
%A Bochtler, Tilmann
%A Hegenbart, Ute
%A Kunz, Christina
%A Benner, Axel
%A Kimmich, Christoph
%A Seckinger, Anja
%A Hose, Dirk
%A Goldschmidt, Hartmut
%A Granzow, Martin
%A Dreger, Peter
%A Ho, Anthony D
%A Jauch, Anna
%A Schönland, Stefan O
%T Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.
%J Blood
%V 128
%N 4
%@ 1528-0020
%C Stanford, Calif.
%I HighWire Press
%M DKFZ-2017-01651
%P 594 - 602
%D 2016
%X Cytogenetic aberrations detected by interphase fluorescence in situ hybridization (iFISH) of plasma cells are routinely evaluated as prognostic markers in multiple myeloma. This long-term follow-up study aimed to assess the prognosis of systemic light chain amyloidosis (AL) patients treated with high-dose melphalan (HDM) chemotherapy and autologous stem cell transplantation, depending on iFISH results. Therefore, we analyzed a consecutive cohort of 123 AL patients recruited from 2003 to 2014. HDM was safe, with only 1 of 123 patients dying as a result of treatment-related mortality, and effective, with a complete remission (CR) rate of 34
%K Immunoglobulin Light Chains (NLM Chemicals)
%K Melphalan (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27257181
%R 10.1182/blood-2015-10-676361
%U https://inrepo02.dkfz.de/record/125525